DYAX: Summary for Dyax Corp. - Yahoo! Canada Finance - Share Prices, Charts, News and more

MORE ON DYAX

Quotes

Summary

Charts

News & Info

Company

Analyst Coverage

Ownership

Financials

Dyax Corp. (NGM:DYAX) Delayed quote data

Last Trade:	3.23 USD
Trade Time:	Feb 9
Change:	0.00 (0.00%)
Prev Close:	3.23
Open:	N/A
Bid:	2.86 x 100
Ask:	N/A
1y Target Est:	7.06

Day's Range:	N/A - N/A
52wk Range:	1.55 - 4.69
Volume:	0
Avg Vol (3m):	1,050,490
Market Cap:	252.10M
P/E (ttm):	N/A
EPS (ttm):	-0.69
Div & Yield:	N/A (N/A%)

1d 5d 3m 6m 1y 2y 5y max

Add DYAX to Portfolio

Download Data

HEADLINES

•	KALBITOR® (ecallantide) Now Commercially Available
	Business Wire (Tue, Feb 2)

•	Dyax Corp. to Present at the BIO CEO & Investor Conference
	Business Wire (Mon, Feb 1)

•	Dyax Launches HAE Hope, A New Online Resource for Patients with Hereditary Angioedema
	Business Wire (Thu, Jan 14)

•	3 Stocks in a Tailspin
	at Motley Fool (Mon, Dec 28)

•	Buy a Company, Get the Plant for Free
	at Motley Fool (Fri, Dec 18)

•	Merck buys British maker of biotech medicines
	AP (Thu, Dec 17)

•	6 Stocks Losing Top Investor Support
	at Motley Fool (Wed, Dec 16)

•	Cubist's acquisition to add value
	Zacks.com (Wed, Dec 16)

•	DYAX CORP Files SEC form 8-K, Other Events, Financial Statements and Exhibits
	EDGAR Online (Fri, Dec 4)

•	DYAX CORP Files SEC form 8-K, Other Events, Financial Statements and Exhibits
	EDGAR Online (Thu, Dec 3)

•	I Love This Industry
	at Motley Fool (Thu, Dec 3)

More Headlines for DYAX...

ANALYST

EPS Est (next year) (Dec-09) :	-0.96
EPS Est (in 2 years) (Dec-10) :	-0.51
Avg Rec (current)*:	1.4
PEG Ratio:	N/A

* (Strong Buy) 1.0 - 5.0 (Strong Sell)

Analyst Opinion - Estimates

BUSINESS SUMMARY

Dyax Corp., a clinical stage biopharmaceutical company, engages in the discovery, development, and commercialization of biotherapeutics for oncology and inflammatory indications.

Full Company Profile

Add to Portfolio

Email to a Friend

•

	Sign In [New User? Sign Up]	Finance Home \|Help

Dyax Corp. (DYAX)